These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 19290557)

  • 1. Procedures and methods of benefit assessments for medicines in Germany: give the child a name.
    Schünemann H; Kunz R; Falck-Ytter Y; Santesso N
    Eur J Health Econ; 2009 May; 10(2):237-8. PubMed ID: 19290557
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to the expertise: procedures and methods of benefit assessments for medicines in Germany, by Geertruida E. Bekkering and Jos Kleijnen.
    Koch K; Lange S
    Eur J Health Econ; 2009 May; 10(2):233-6. PubMed ID: 19123011
    [No Abstract]   [Full Text] [Related]  

  • 3. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Procedures and methods of benefit assessments for medicines in Germany - a comment - letter no. 2].
    Schünemann HJ; Kunz R; Falck-Ytter Y
    Dtsch Med Wochenschr; 2009 Feb; 134(7):319-20; author reply 320. PubMed ID: 19197817
    [No Abstract]   [Full Text] [Related]  

  • 5. [Procedures and methods of benefit assessments for medicines in Germany - a comment - letter no. 1].
    Koch K; Lange S
    Dtsch Med Wochenschr; 2009 Feb; 134(7):317-9; author reply 320. PubMed ID: 19197816
    [No Abstract]   [Full Text] [Related]  

  • 6. Evidence-based benefit assessment of pharmaceuticals as a basis for rational and economical pharmaceutical therapy.
    Müller T
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():1-3. PubMed ID: 18987904
    [No Abstract]   [Full Text] [Related]  

  • 7. [Surveillance studies criticized. A marketing effort for expensive drugs? "Not throwing the baby out with the bath water" (interview by Dr. Beate Schumacher)].
    Selbmann HK
    MMW Fortschr Med; 2009 Aug; 151(34-35):6. PubMed ID: 19771776
    [No Abstract]   [Full Text] [Related]  

  • 8. [Reform in evidence based medicine. Where is solidarity?].
    el-Din MD
    MMW Fortschr Med; 2002 Dec; 144(50):18. PubMed ID: 14610861
    [No Abstract]   [Full Text] [Related]  

  • 9. [Cost/benefit analysis of a regional drug surveillance center].
    Mignot G; Chichmanian RM; Spreux A; Bernard G
    Therapie; 1988; 43(5):377-8. PubMed ID: 3147546
    [No Abstract]   [Full Text] [Related]  

  • 10. [New EBM: is it really so detrimental to physicians?].
    Schmidt K
    MMW Fortschr Med; 2004 Sep; 146(39):56-7. PubMed ID: 15532417
    [No Abstract]   [Full Text] [Related]  

  • 11. [Value-based medicine in ophthalmology].
    Finger RP
    Ophthalmologe; 2010 Mar; 107(3):213. PubMed ID: 20024565
    [No Abstract]   [Full Text] [Related]  

  • 12. [Illegal drug trade discovered in Bavaria. How can we protect ourselves from drug falsification?].
    Schweim HG
    MMW Fortschr Med; 2005 Sep; 147(38):11. PubMed ID: 16218221
    [No Abstract]   [Full Text] [Related]  

  • 13. [What is the cost of drug quality?].
    Hannse H
    Fortschr Med; 1975 Aug; 93(24):1083-4, 1112-3. PubMed ID: 818000
    [No Abstract]   [Full Text] [Related]  

  • 14. [The "right" way for nursing].
    Köpke S
    Pflege Z; 2008 Mar; 61(3):125. PubMed ID: 18450255
    [No Abstract]   [Full Text] [Related]  

  • 15. [The future of German surgery lies in documentation by transparent outcome quality].
    Sawicki PT
    Chirurg; 2008 Nov; Suppl():371-2. PubMed ID: 19367751
    [No Abstract]   [Full Text] [Related]  

  • 16. [Evidence-based surgery. What is really verified?].
    Jähne J
    Chirurg; 2011 Dec; 82(12):1065-6. PubMed ID: 22090012
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk-sharing agreements for innovative drugs: a new solution to old problems?
    de Pouvourville G
    Eur J Health Econ; 2006 Sep; 7(3):155-7. PubMed ID: 16912890
    [No Abstract]   [Full Text] [Related]  

  • 18. Should evidence-based proof of efficacy as defined for a specific therapeutic agent be extrapolated to encompass a therapeutic class of agents?
    Antman EM; Ferguson JJ
    Circulation; 2003 Nov; 108(21):2604-7. PubMed ID: 14638523
    [No Abstract]   [Full Text] [Related]  

  • 19. ["There are clear criteria for product surveillance studies"].
    Throm S
    MMW Fortschr Med; 2009 Aug; 151(34-35):7. PubMed ID: 19771777
    [No Abstract]   [Full Text] [Related]  

  • 20. [Which evidence is adequate in geriatric patients?].
    Sieber CC
    Dtsch Med Wochenschr; 2015 Dec; 140(24):1795-6. PubMed ID: 26625225
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.